CP10 (CJC + IPA)

Two switches for the same gland: that is the principle behind CP10. The ready-made mixture pairs CJC-1295 without DAC (Mod GRF 1-29) with ipamorelin at a fixed ratio, and each component addresses the pituitary through its own route.

• CJC-1295 without DAC is a GHRH analogue with an altered amino acid sequence that protects it from proteolytic breakdown. It binds to GHRH receptors in the anterior pituitary and starts the release of growth hormone via the cAMP signalling route.
• Ipamorelin is a selective agonist at the receptor GHS-R1a, better known as the ghrelin receptor. Its signal triggers GH release more directly and faster.

When both signals meet, they reinforce each other. In research models the combination is linked with three- to five-fold higher GH peaks compared with either substance alone. Two properties make the pairing particularly popular in secretagogue research: first, release stays pulse-like and thus close to the physiological pattern, which is discussed as an advantage over the direct administration of growth hormone. Second, ipamorelin leaves cortisol and prolactin largely untouched, unlike non-selective secretagogues such as GHRP-6.

The mixture thus ranks among the most frequently examined combinations in the field of growth hormone secretagogues. Having both peptides already together in the vial spares separate dissolving and measuring and keeps the ratio of the components constant. If you look through the literature on GH secretagogues, you will meet this pair more often than almost any other combination.

Both peptides stimulate the body's own pulse-like release of growth hormone, and ipamorelin does not noticeably alter cortisol or prolactin in studies. Long-term human data do not exist; the assessment rests on short studies and anecdotal reports.

• Injection site: redness, a feeling of pressure or a brief irritation after subcutaneous administration, the most frequent observation.
• Typical of growth hormone: water retention that passes, plus numb or tingling hands resembling carpal tunnel syndrome, usually amount-dependent and reversible.
• Glucose metabolism: a raised GH level can lift fasting blood sugar and temporarily lower sensitivity to insulin in studies.
• Tiredness or grogginess shortly after administration, in line with the GH peak.

This summary is no substitute for medical advice.

• Ipamorelin, the first selective growth hormone secretagogue - first description of ipamorelin and its selectivity: GH release without appreciable effect on cortisol and prolactin.
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers - model of uptake, breakdown and effect of ipamorelin in volunteers.
• Prolonged Stimulation of GH and IGF-I by CJC-1295 - pharmacokinetics and activity profile of the CJC-1295 backbone.
• Human GHRF-albumin bioconjugates - identification of CJC-1295 - mechanism of GHRH receptor activation.